Tarsus Pharmaceuticals, Inc.·4

Mar 17, 4:24 PM ET

Azamian Bobak R. 4

Research Summary

AI-generated summary

Updated

Tarsus CEO Bobak Azamian Receives 66,274 Shares (RSU Settlement)

What Happened

  • Bobak R. Azamian (President/CEO and Board Chair) had 66,274 restricted stock units (RSUs convert/settle into shares) on March 15, 2026. The filing shows 66,274 shares issued (acquired) and the same total split into four derivative "disposed" line items (11,300; 16,975; 23,121; 14,878) reported at $0.00.
  • The acquisition line is listed as an RSU settlement (derivative conversion). The $0.00 disposition entries indicate shares were transferred/withheld (commonly for taxes or related obligations), not sold for cash. No cash proceeds or market-sale prices are reported.

Key Details

  • Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely filing).
  • Reported activity: 66,274 shares issued on RSU settlement; 11,300 + 16,975 + 23,121 + 14,878 shares reported disposed at $0.00.
  • Prices/values: Acquisition price listed as N/A; dispositions reported at $0.00 (no cash proceeds shown).
  • Shares owned after transaction: not provided in the supplied data.
  • Notable footnotes: shares issued pursuant to vested RSUs (F1); reporting person is trustee of the Bobak Azamian Living Trust (F2); each RSU converts to one share (F3); the RSUs originate from grants under the 2020 Stock Plan with typical 25% annual vesting schedules (grants from 2022–2025 per F4–F7).

Context

  • These entries reflect RSU settlement and subsequent withholding/transfers (the $0.00 dispositions are typical when shares are retained to satisfy tax withholding or similar obligations), not open-market sales or purchases.
  • This is an award/vesting event rather than a buy or sell decision; it does not by itself signal insider sentiment about the company.